Virus-specific T cells (VSTs) represent a groundbreaking approach to treating viral infections post-transplant. By reprogramming immune cells to recognize and attack virus-infected cells, VST therapy provides precise, long-lasting protection. Researchers are exploring VSTs for CMV, EBV, and adenovirus infections, offering hope for immunocompromised patients. Xellera Therapeutics suppo... https://www.xelleratherapeutics.com/services/custom-manufacturing-services/